Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Puts Hold On Adaptive Trials, Wants More Clarity On Basics

Executive Summary

FDA would like to slow the escalating momentum behind adaptive clinical trial designs to allow time to craft better working definitions of the new models and build a better base before moving forward, agency officials indicated at a Pharmaceutical Research & Manufacturers of America workshop
Advertisement

Related Content

Adaptive Trials Could Have A Steep Regulatory Learning Curve
Adaptive Trials Could Have A Steep Regulatory Learning Curve
Adaptive Trials Could Have A Steep Regulatory Learning Curve
Adaptive Trials Could Have A Steep Regulatory Learning Curve
Late-Stage Trials Pose Challenge As FDA Molds Adaptive Design Guidance
Late-Stage Trials Pose Challenge As FDA Molds Adaptive Design Guidance
Industry Encouraged To Spread Its Wings In Learn Phase of Adaptive Trials
Ready Or Not: FDA Accepting Adaptive Trial Applications
Ready Or Not: FDA Accepting Adaptive Trial Applications
PDUFA IV: FDA Stresses Burden Of Industry Meetings In User Fee Discussions
Advertisement
UsernamePublicRestriction

Register

PS047783

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel